Entropy Neurodynamics Limited has released a press release.
Phase 1b determines optimal parameters for TRP-8803 use
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- $6m funding to fast track TRP-8803 clinical trial strategy
- Pause in Trading
- TRP-8803 doses deemed safe by SRC following phase 1b study
- Preliminary Final Report Reporting Adjustments
- Appendix 4E Preliminary Final Report
Later from Entropy Neurodynamics
- Phase 1b extension results meet study objectives
- Positive interim results in Phase 2a TRP-8802 IBS trial
- Appendix 4D and Half Year Report for period 31 Dec 2024
- TRP-8803 BED trial to commence with Swinburne this quarter
- Binge Eating Disorder Trial receives Human Ethics approval
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics